Science

Science

Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.

Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.

Science

We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.

Science

Our CMC model enables us to rapidly and reliably progress novel treatments from ideation to the clinic.

Science

Our development process allows us to successfully execute highly efficient program timelines with cutting-edge technologies while ensuring quality is never sacrificed.

Pipeline

Fueling a pipeline of best-in-class therapies for a range of diseases.

Our business model centers on bringing transformative therapies to patients as rapidly as possible. Our product candidate pipeline demonstrates our progress, with multiple programs in the clinic and the leading program having entered the clinic less than two years from ideation.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR004 (APG777)

Clinical

PR001 (APG808)

Clinical

PR007 (APG990)

Clinical

PR012 (APG222)

Ind-Enabling

PR018 (APG333)

Discovery

Rights/Partner

Apogee logo

Apogee Therapeutics is the first company to be formed around assets discovered by and licensed from Paragon. Established in 2022, Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR011 (SPY001)

Clinical

PR010 (SPY002)

Ind-Enabling

PR014 (SPY003)

Ind-Enabling

PR026 (SPY120)

Ind-Enabling

PR022 (SPY130)

Ind-Enabling

PR025 (SPY230)

Ind-Enabling

Rights/Partner

Spyre Logo

Spyre Therapeutics is the second company to be formed around assets discovered by and licensed from Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR035 (ORKA-001)

Ind-Enabling

PR029 (ORKA-002)

Ind-Enabling

PR059 (ORKA-003)

Discovery

Rights/Partner

Oruka Logo

Oruka Therapeutics is the third company to be formed around assets discovered by and licensed from Paragon. Established in 2024, Oruka is advancing a pipeline of potentially best-in-class biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR030 (JADE-001)

Discovery

PR041 (JADE-002)

Discovery

PR050 (JADE-003)

Discovery

Rights/Partner

Jade Biosciences Logo

Jade Biosciences is the fourth company to be formed around assets discovered by and licensed from Paragon. Jade is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR054 (CR-001)

Discovery

PR062 (CR-002)

Discovery

PR023 (CR-003)

Discovery

Rights/Partner

Crescent Biopharma Logo

Crescent Biopharma is the fifth company to be formed around assets discovered by and licensed from Paragon. Crescent is advancing a pipeline of precision-engineered molecules designed to advance care for patients with solid tumors.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR002

Ind-Enabling

PR013

Discovery

Rights/Partner

Undisclosed

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

Multiple internal programs

Discovery

Discovery

Discovery

Rights/Partner

Paragon logo

Partners

Driving rapid progress and patient impact.

Our scientific approach and expertise have generated the assets that serve as the foundation for several successful companies devoted to bringing transformative treatments to patients living with significant unmet medical conditions.

Apogee Logo

ABOUT APOGEE THERAPEUTICS

Apogee Therapeutics is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. Based in San Francisco, CA, Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and is backed by leading healthcare investors. Visit their website for more details. Follow Apogee on LinkedIn.

Spyre Logo

ABOUT SPYRE THERAPEUTICS

Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. The company was founded in 2023 by Fairmount and is based in Waltham, MA. Visit their website for more details. Follow Spyre on LinkedIn.

Oruka Logo

ABOUT ORUKA THERAPEUTICS

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were licensed from Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Visit their website for more details. Follow Oruka on LinkedIn.

Jade Biosciences Logo

ABOUT JADE BIOSCIENCES

Jade Biosciences is developing transformative therapies with the goal of redefining the standard of care for autoimmune diseases. The company launched in July 2024 and has raised $300 million from a strong slate of investors: Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, Braidwell LP, Frazier Life Sciences, and Versant Ventures. Jade’s portfolio was licensed from Paragon Therapeutics. Visit their website for more details. Follow Jade on LinkedIn.

Crescent Biopharma Logo

ABOUT CRESCENT BIOPHARMA

Crescent BioPharma is a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company’s pipeline of three programs harness proven biology to accelerate the path to market for potentially best in class therapeutics. Visit their website for more details. Follow Crescent on LinkedIn.

Team

Dedicated experts with a passion for improving health outcomes.

Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.

Evan Thompson Headshot

Evan Thompson, Ph.D.

CHIEF OPERATING OFFICER

View Bio
Hussam Shaheen Headshot

Hussam Shaheen, Ph.D.

HEAD OF RESEARCH

View Bio
Keri Lantz Headshot

Keri Lantz

HEAD OF FINANCE

View Bio
Damon Banks Headshot

Damon Banks, Ph.D., J.D.

HEAD OF LEGAL

View Bio
Jason Oh Headshot

Jason Oh, Ph.D.

SENIOR VICE PRESIDENT OF BIOLOGY

View Bio
Shawn Russell Headshot

Shawn Russell, Ph.D.

SENIOR VICE PRESIDENT OF CHEMISTRY, MANUFACTURING, AND CONTROLS

View Bio
Neta Batscha Headshot

Neta Batscha

SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND OPERATIONS

View Bio
Mike Meehl Headshot

Michael Meehl, Ph.D.

SENIOR VICE PRESIDENT OF BIOLOGICAL RESEARCH

View Bio
Cyrus Stacey Headshot

Cyrus Stacey

VICE PRESIDENT OF QUALITY

View Bio
Joe Russo Headshot

Joe Russo

EXECUTIVE DIRECTOR OF FINANCE PLANNING AND ANALYSIS

View Bio
Archit Sheth-Shah Headshot

Archit Sheth-Shah

SENIOR DIRECTOR OF PORTFOLIO STRATEGY

View Bio
Byron Kwan Headshot

Byron Kwan, Ph.D.

DIRECTOR OF BIOTHERAPEUTICS

View Bio
Bernard Liu Headshot

Bernard Liu, Ph.D.

DIRECTOR OF BIOTHERAPEUTICS

View Bio
Danielle Mallay Headshot

Danielle Malloy

DIRECTOR OF LEGAL OPERATIONS

View Bio
Daniel Rios Headshot

Daniel Rios, Ph.D.

DIRECTOR OF BIOLOGY

View Bio
Pamela Howley Headshot

Pamela Howley

DIRECTOR OF CHEMISTRY, MANUFACTURING, AND CONTROLS

View Bio
Andrew Schirmer Headshot

Andrew Schirmer

Associate Director of Manufacturing

View Bio
M. Murshid AlamAlam Headshot

M. Murshid Alam, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Erin Clark Headshot

Erin Clark, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Byong Ha Kang Headshot

Byong Ha Kang, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Jake Milligan Headshot

Jake Milligan, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Kevin Kramer Headshot

Kevin Kramer, Ph.D.

Senior Scientist

View Bio
Lauren Maslin Headshot

Lauren Maslin, Ph.D.

SENIOR ASSOCIATE

View Bio
Rita Vaz Headshot

Rita Vaz, Ph.D.

SENIOR DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT

View Bio
Soraia Oliveira Headshot

Soraia Oliveira, Ph.D.

Senior Project Manager for Antibody Discovery and Development

View Bio
Joana Ministro Headshot

Joana Ministro, Ph.D.

SENIOR PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT

View Bio
Joana Vidal Silva Headshot

Joana Vidal Silva

PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT

View Bio
Mark Heffernan Headshot

Mark Heffernan

SENIOR DIRECTOR AND CORPORATE CONTROLLER

View Bio
Melissa Donnarummo Headshot

Melissa Donnarummo

Director of Project Accounting

View Bio
Jodie Raye Headshot

Jodie Raye

SENIOR ACCOUNTANT

View Bio
Eric Pohle Headshot

Eric Pohle

ASSOCIATE DIRECTOR OF FINANCIAL PLANNING AND ANALYSIS

View Bio
Jill Igoe Headshot

Jill Igoe

ACCOUNTS PAYABLE MANAGER

View Bio
Lauren Gillis Headshot

Lauren Gillis

DIRECTOR OF EXECUTIVE ADMINSTRATION

View Bio
Sophia Medina Headshot

Sophia Medina

ADMINISTRATIVE ASSISTANT

View Bio
Alison Fiore Headshot

Alison Fiore

ADMINISTRATIVE ASSISTANT

View Bio
About usAbout us
Fairmount

About Us

Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics and complex biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies.

News

The latest Paragon news and developments.

Arrow
Arrow
Join Us

Join Us

Be a part of our innovative team.

We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.

VIEW POSITIONS ON LINKEDIN

VALUES

Powered by our dedication and commitment to improve the lives of patients with high unmet needs.

Our values reflect who we are and guide our actions and decisions, empowering everyone to contribute meaningfully to our shared purpose.

Team First

We respect and value each other’s ideas and contributions. We achieve more by working together.

Uphold a High Bar

We build best-in-class therapies that are impactful for patients. We aim to improve with every iteration, striving for long-term excellence.

Experimentalists at Heart

We are open-minded and data-driven. We constantly adapt and evolve as new information emerges.

Bias Toward Action

We work with a sense of urgency to advance therapeutic programs to the clinic rapidly and efficiently.

Keep It Fun

We celebrate our successes and our opportunities to learn. We are passionate about our work and our play.

Contact

For media inquiries or more information: